skip to content

Other

'Abzena inside' study data to be presented at ASH

23 November 2016 09:26

Abzena notes that Opsona Therapeutics Ltd has announced that preliminary results from its ongoing Phase I/II study of 'Abzena inside' product OPN-305 in second line lower risk myelopdysplastic syndrome ('MDS') patients will be presented at the 58th annual meeting of the American Society of Haematology (ASH) in San Diego on 3 December.

At 9:26am: (LON:ABZA) Abzena Plc share price was 0p at 32.5p

Story provided by StockMarketWire.com

Related Company: ABZA

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

-

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.